MANCHESTER, England--(BUSINESS WIRE)--Synexus, the world’s leading organisation dedicated to the recruitment and running of clinical trials, is continuing its commitment to growth in Europe, with the appointment of Efim Borodowski as Director, International Business Development.
Efim, who joins Synexus from Fisher Clinical Services in Switzerland, will report to Jeremy Hickling, Senior Vice President, Portfolio Management. Efim Borodowski will also work closely with Helena Sigal, Head of Operations in Germany, and Susanne Groblschegg, Country Manager for Austria. Commenting on the new appointment to his team, Jeremy Hickling said: “Following our acquisition of thirteen new sites in Western Europe and the CEE at the tail end of last year, we have been working hard during 2010 to build an experienced and dynamic business development team, which will help us further develop our presence in both regions. Efim is central to this and we are delighted to have him on board.”
Efim, who has considerable experience in the clinical trials sector, including biological sample management, distribution and laboratory services, will be focusing on key pharmas and CROs in both Germany and Austria, and working with the International Sales team to generate increased business with existing and new clients.
- ENDS -
Synexus notes:
Synexus®
headquartered in Manchester, England, is the world’s largest
multi-national company dedicated to the recruitment and running of
clinical trials at its own research centres across the globe on behalf
of its pharmaceutical, biotech and CRO clients. Synexus now has 26
Dedicated Research Centres across the UK, Germany, Austria, Poland,
Hungary, Ukraine, Bulgaria, India and South Africa staffed by full-time
GCP-trained investigators.
The traditional way of recruiting for clinical trials through individual doctors is still by far the most common method, despite the fact that each doctor only recruits an average of five patients per study and more than 60 percent recruit one or less. This incredibly costly model remains the norm.